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Abstract
In the last 10 years, options for treating patients with diffuse large B-cell lymphoma (DLBCL)
have greatly expanded. In randomized clinical studies, the addition of rituximab to cyclophos-
phamide, vincristine, doxorubicin, prednisone (CHOP) delivered every 3 weeks (R-CHOP)
has been associated with improved survival rates, without increased toxicity, in all patient
groups studied. Another strategy, giving patients dose-dense CHOP — CHOP every 2 weeks or
CHOP-14 — has also been found appropriate for all patients between the ages of 18 and
75 years but probably not superior to R-CHOP-21. Strategies with dose-intense regimens are
currently tested for improving the outcome of young patients with poor risk DLBCL. In elderly
patients, improvement in outcomes might be caused by the addition of another drug to the
R-CHOP regimen. Elderly patients are best treated with R-CHOP if they do not have severe
concomitant diseases.
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Streszczenie
W ostatniej dekadzie odnotowano istotne zwiększenie możliwości terapeutycznych u chorych
z chłoniakami rozlanymi z dużych komórek B (DLBCL). W randomizowanych badaniach
klinicznych wykazano, że dodanie rytuksymabu do schematu cyklofosfamid, winkrystyna,
doksorubicyna, prednizon (CHOP), stosowanego co 3 tygodnie (R-CHOP) przyczyniło się do
wydłużenia czasu przeżycia wszystkich badanych grup chorych bez nasilenia toksyczności.
Inna strategia, polegająca na skróceniu odstępu pomiędzy kolejnymi cyklami CHOP do 2 tygo-
dni (CHOP-14), również wydaje się możliwa do zastosowania u wszystkich chorych w wieku
18–75 lat, ale prawdopodobnie nie jest bardziej skuteczna niż R-CHOP-21. Strategie zwiększające
intensywność dawki są obecnie badane z intencją poprawy wyników leczenia u młodszych chorych
z DLBCL o wysokim ryzyku. U chorych w starszym wieku poprawy wyników leczenia można się
spodziewać po dołączeniu innych leków do schematu R-CHOP. W przypadku niewystępowania
ciężkich chorób towarzyszących jest to wciąż zalecany schemat leczenia w tej grupie wiekowej.
Słowa kluczowe: chłoniaki nieziarnicze, chłoniak rozlany z dużych komórek B, CHOP,
rytuksymab, intensywność dawki, podeszły wiek
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Introduction
Non-Hodgkin lymphoma (NHL) remains a sub-
stantial contributor to the incidence of and mortali-
ty associated with cancer in Europe. European can-
cer registry data suggest that the incidence of NHL
had been increasing till the mid-1990s, and then
began to plateau [1–3]. In 2006, an estimated 72,800
new cases were diagnosed, up from 62,300 in 2004
[4, 5]. Non-Hodgkin lymphoma accounted for 3.2%
of new cancer cases, 2.8% of all cancer deaths, and
became the eighth leading cause of new cancer ca-
ses and the tenth leading cause of cancer deaths in
Europe in 2006 [4].
The most common form of NHL is diffuse lar-
ge B-cell lymphoma (DLBCL), which accounts for
30% to 35% of NHL cases [6]. The incidence of
DLBCL increases with advancing age, such that the
disease represents 54% of NHL cases among pa-
tients older than 75 years [7]. For nearly 3 deca-
des, the standard of care for patients with DLBCL
was cyclophosphamide, vincristine, doxorubicin,
prednisone (CHOP), which was established in 1976
as a regimen that induced high rates of overall re-
sponse and complete remission in patients with
advanced NHL [8]. CHOP was later proved to be
superior to more complicated regimens in respect
to the cost and severity of toxicity, and equally ef-
fective in terms of disease-free and overall survi-
val rates [9]. Still, the cure rate with CHOP was
suboptimal, with 10-year progression-free survival
(PFS) and overall survival (OS) rates by approxi-
mately 30% and 35%, respectively [9].
An important limitation of the reported data was
that physicians were circumspect in treating people
over 60 years of age, who constitute more than 50%
of patients with aggressive NHL [10]. Even after
CHOP was established as the standard of care, many
older patients with DLBCL were treated without do-
xorubicin, or treatment was completely withheld be-
cause of concerns about cardiotoxicity and other po-
tential side effects. According to the analysis of
a Dutch population-based NHL registry between
1981 and 1989, that studied CHOP in patients with
DLBCL stratified into 5 age groups (< 60, 60–64,
65–69, 70–74, and > 75 y) , rates of complete respon-
se (CR) progressively declined after age 65, and relati-
ve 5-year OS progressively declined after age 60 [7].
This manuscript reviews studies of three stra-
tegies that have been proven to improve outcomes
for patients with DLBCL by the addition of rituxi-
mab to CHOP (R-CHOP), dose intensification of
CHOP, by either dose escalation or densification,
and using R-CHOP in elderly patients.
How to stratify patients with DLBCL?
The International Prognostic Index (IPI) was
described more than 15 years ago and remains the
best prognostic indicator for patients with DLBCL,
as shown in Figure 1 [10]. In this study, all DLBCL
patients, who have entered randomized studies
Figure 1. Survival in 6696 patients included in the Groupe d’Etude des Lymphomes de l’Adulte (GELA) randomized
studies for whom all parameters of the International Prognostic Index (IPI) were present at diagnosis. A. Progression-
-free survival (PFS); B. Overall survival (OS)
Rycina 1. Przeżycie 6696 chorych przydzielonych metodą randomizacji do badań Groupe d’Etude des Lymphomes
de l’Adulte (GELA), dla których wszystkie parametry wchodzące w skład Międzynarodowego Indeksu Rokowniczego (IPI)
były znane w chwili rozpoznania. A. Czas do progresji choroby (PFS); B. Całkowity czas przeżycia (OS)
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from the Groupe d’Etude des Lymphomes de l’Adulte
(GELA), and who had parameters to calculate the
IPI at diagnosis were analyzed. It clearly showed
the difference according to the number of adverse
prognostic parameters present at diagnosis. Since
then, numerous studies have tried to describe
a better index with the addition of biological or ge-
netic parameters, but with no success. This was ma-
inly due to the fact that the new parameters were
not standardized and have not been analyzed in lar-
ge prospective studies [11].
Increased age is associated with the presence
of concommitant diseases. It also decreases the
ability of patients to tolerate treatments, and thus,
physicians have a tendency to decrease the inten-
sity of chemotherapy in these patients [12]. It re-
sults in poorer outcomes in elderly patients [13].
Patiens are stratified according to age taken as
a putative index of treatment feasibiliy. In 1980’s,
60 years was considered as the threshold for elder-
ly patients. This threshold was considered as the
limit for patients entering a study with higher dose
regimens or autologous transplant in first line. Al-
though patients aged 65 can probably tolerate hi-
gher dose regimens, they are at risk for more pro-
nounced complications. Another threshold was re-
cently described for very old patients, older than
80 years of age. These patients have usually several
concommitant diseases that decrease their ability
to tolerate the R-CHOP regimen [14].
Evolution of R-CHOP
as the standard of care
Rituximab is a human-murine IgG1 monoclo-
nal antibody against the B-cell surface antigen
CD20, which is routinely expressed in patients with
DLBCL and other B-cell lymphomas. The first ran-
domized study of a rituximab-chemotherapy com-
bination in lymphoma was the LNH98-5 trial of
GELA which compared R-CHOP with CHOP in ol-
der patients (60–80 y) with DLBCL [15–17]. With
a median follow-up of 2 years, then 5 and 10 years,
the results showed that R-CHOP significantly in-
creases the CR rate, improved event-free survival
(EFS), disease-free survival and overall survival
(OS), and strongly decreased the rates of treatment
failure and relapse, compared with standard CHOP
alone (Figure 2). These improvements occurred in
patients ≥ 70 years old and in those with scores of
2 or 3 on the age-adjusted International Prognostic
Index (aaIPI), as well as in lower-risk patients, and
there was no clinically significant increase in toxi-
city. Table 1 provides further details of this trial and
the other studies discussed in this section.
Longer-term analysis of GELA LNH98-5 sho-
wed that the survival benefits extended to up to
7 years, and no long-term toxicity was associated with
R-CHOP [18]. These longer survival rates in the
R-CHOP group were secondary to the lower rate
of disease progression during therapy and fewer
Figure 2. 10-year follow-up of the Groupe d’Etude des Lymphomes de l’Adulte (GELA) study comparing cyclopho-
sphamide, vincristine, doxorubicin, prednisone (CHOP) to rituximab-CHOP [17] A. Progression-free survival (PFS);
B. Overall survival (OS)
Rycina 2. Dziesięcioletni okres obserwacji wyników badania Groupe d’Etude des Lymphomes de l’Adulte (GELA),
w którym porównano stosowanie schematu cyklofosfamid, winkrystyna, doksorubicyna, prednizon (CHOP) ze schema-
tem CHOP w połączeniu z rytuksymabem [17]. A. Czas do progresji choroby (PFS); B. Całkowity czas przeżycia (OS)
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Table 1. Comparisons of cyclophosphamide, vincristine, doxorubicin, prednisone (CHOP) vs. rituximab-CHOP
(R-CHOP)
Tabela 1. Porównanie schematu cyklofosfamid, winkrystyna, doksorubicyna, prednizon (CHOP) ze schematem
CHOP w połączeniu z rytuksymabem (R-CHOP)
Study Population Design* Primary outcome Safety results
measure(s) (95% CI)
GELA LNH98-5 399 patients with Random assignment 2-y EFS: No significant
(Coiffier et al., untreated DLBCL, to 8 cycles of CHOP CHOP: 38% (32–45%) difference between
2002)   age 60–80 y   or R-CHOP R-CHOP: 57% (50–64%) groups in clinically
p < 0.001    relevant toxicity
Longer-term As above As above 5-y EFS: No long-term
analysis of CHOP: 29% (23–36%)  toxicity appeared
GELA LNH98-5 R-CHOP: 47% (40–54%) to be associated
(Feugier et al., p = 0.00002 with R-CHOP
2005)
US Intergroup 632 patients with Random assignment 3-y FFS after Not reported
trial (Habermann untreated DLBCL, to CHOP or R-CHOP induction therapy:
et al., 2005)  age ≥ 60 y   (6 or 8 cycles, CHOP: 46%
depending on response R-CHOP: 53%
after 4 cycles; R was admini- HR = 0.78
stered 7 and 3 days before (0.61–0.99);
cycle 1, and 2 days before p = 0.04
cycles 3, 5, and 7)
415 responders Estimated 2-y FFS
to CHOP or R-CHOP were after second
randomly assigned to obser- random
vation or maintenance R assignment:
(4 courses at maintenance R: 76%
6-mo intervals) observation: 61%
HR = 0.63
(0.44–0.90);
p = 0.009
Canadian 292 patients with Retrospective database 2-y PFS: Not reported
population-based advanced DLBCL, analysis comparing without R: 51%
analysis (Sehn median age 64 y 140 patients treated with R: 69%
et al., 2005) (range, 19–86 y)    with CHOP-like RR = 0.56
chemotherapy (median (0.39–0.81);
follow-up 42 mo) p = 0.002
and 152 patients treated 2-y OS:
with CHOP-like without R: 52%
chemotherapy + R (median with R: 78%
follow-up 24 mo) RR = 0.40
(0.27–0.61);
p < 0.0001
MInT (Pfreundschuh 326 patients†, Random assignment Estimated 3-y EFS: No significant
et al., 2006a) age 18–60 y, with to 6 cycles of CHOP-like without R:  difference between
good-prognosis chemotherapy alone  68% (62–73%) groups in frequency
untreated DLBCL or with R with R: 85% of adverse events
(aaIPI = 0–1 in stage (81–89%)
II–IV disease, or stage I p < 0.0001
disease with bulk)
DSHNHL 1222 patients, Random assignment Estimated 3-y EFS: Not reported
RICOVER-60 age 61–80 y, with DLBCL to 6 or 8 6 × CHOP-14: 47%
(Pfreundschuh with DLBCL cycles of CHOP-14, 8 × CHOP-14: 53%
et al., 2006c) with or without R 6 × R-CHOP-14: 66%
(regardless of the 8 × R-CHOP-14: 63%
number of cycles, EFS compared
8 R infusions with 6 × CHOP-14†:
were given) 8 × CHOP-14:
RR = 0.76;
p = 0.017
6 × R-CHOP-14:
RR = 0.51;
p < 0.001
8 × R-CHOP-14:
RR = 0.54;
p < 0.001
HOVON (Sonneveld 243 patients* , 8 cycles of Estimated 2-y FFS: 64% of patients
et al., 2006)  age ≥ 65 y, with CHOP-14 with CHOP-14: 33% completed planned
untreated random assignment R-CHOP-14: 55% treatment; 22%
intermediate- to receive or not HR = 0.60; of patients went off
or high-risk receive 6 infusions p = 0.007 treatment due to
B-cell NHL of R (G-CSF support in toxicity; 15% of patients
both arms) < 70 y went off
treatment due to toxicity
*Regimens were given at standard doses unless specified otherwise; †trial was stopped prematurely; 824 patients were enrolled; aaIPI — age-adjusted Interna-
tional Prognostic Index; CI — confidence interval; DLBCL — diffuse large B-cell lymphoma; EFS — event-free survival; FFS — failure free survival; GELA — Groupe
d’Etude des Lymphomes de l’Adulte; HR — hazard ratio; MInT — MabTher International Trial; mo — months; OS — overall survival; PFS — progression-free sur-
vival; R — rituximab; RR — risk ratio; y — year(s)
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relapses among patients who had CR; this effect was
still evident at 10 years of follow up [17].
The US Intergroup study also compared
R-CHOP and CHOP in older patients (≥ 60 y) [19].
The double blind, randomized trial addressed the
two major types of treatment failure in aggressive
NHL: the failure of induction therapy and failure to
maintain CR [20]. Patients were initially assigned
to the R-CHOP or CHOP group, and responders re-
ceived either no additional treatment or maintenan-
ce of rituximab for 2 years. Regardless whether ri-
tuximab was part of induction therapy or mainte-
nance after CHOP, it significantly improved
failure-free survival (FFS, the time from random
assignment to relapse, non-protocol treatment, or
death). The rituximab continuing use after R-CHOP
was not shown to be beneficial.
After the 2-year results of GELA LNH98-5
were published, the British Columbia Cancer Agen-
cy recommended R-CHOP for all newly diagnosed
patients with advanced DLBCL, regardless of age
[21]. Investigators then retrospectively analyzed
the outcomes of such patients during a 3-year pe-
riod, 18 months before and after the policy was
implemented. Regardless of patient age and treat-
ment, both PFS and OS were significantly better in
patients treated after the recommendation of R-
-CHOP than in those treated before (with CHOP
alone), even after the investigators controlled for
age and IPI score. Although the follow up length in
the two study groups was different, this study re-
mains very important because it reflects “real life”
and there is no selection bias.
The benefits of R-CHOP also extend to youn-
ger adults with DLBCL who have a good progno-
sis. The MabThera International Trial (MInT), de-
signed by cooperative groups from 18 countries,
was stopped early when it demonstrated the supe-
riority of R-CHOP over CHOP in that patient po-
pulation [22]. At median follow-up of 34 months,
EFS, PFS, and OS were significantly better in pa-
tients who received rituximab plus CHOP or
CHOP-like chemotherapy than in those who rece-
ived only chemotherapy. Only 21% of patients fa-
iled after chemotherapy plus rituximab, compared
with 41% who failed after chemotherapy alone, sug-
gesting that the proportion of young patients who
need salvage treatment could be halved with ritu-
ximab. CHOEP (CHOP plus etoposide) was supe-
rior to CHOP with regard to EFS, but the compari-
son of R-CHOP and R-CHOEP showed no signifi-
cant difference in EFS or overall survival. R-CHOP
is therefore preferable to R-CHOEP because it has
fewer toxic effects.
Thus, the addition of rituximab to CHOP has
been associated with improvements in OS and in
EFS or PFS, without increased toxicity, in all stu-
died patient groups. The addition of rituximab to
CHOP is now considered the standard of care for
treatment of DLBCL with curative intent [23]. How-
ever, no study has addressed the group of young
patients with adverse prognostic factors. R-CHOP
was considered the standard of care, but it was not
demonstrated to allow the same improvement in
terms of survival. In the past, before rituximab era,
it was demonstrated that some regimens with hi-
gher doses of doxorubicin and cyclophosphamide or
with consolidation in first CR with high-dose the-
rapy and autotransplant were better than CHOP for
this purpose. At present time, we do not have defi-
nitive answers about rituximab. Several ongoing
studies examine this subject but none has curren-
tly been presented. The GELA has released the in-
terim analysis of the LNH03-2B study comparing
R-CHOP to rituximab combined with the ACVBP
regimen, a high-dose CHOP-like regimen to be
superior to CHOP in some subgroups of DLBCL
patients (Figure 3) [24]. This interim analysis with
185 of the 380 randomized patients shows an iden-
tical CR rate between the two regimens but a lon-
ger not yet statistically significant EFS and a signi-
ficantly longer DFS (p = 0.024) for patients treated
Figure 3. Design of the Groupe d’Etude des Lympho-
mes de l’Adulte (GELA) study comparing R-CHOP-21
to R-ACVBP. This study has acrued 380 patients with
a primary endpoint of event-free survival
Rycina 3. Założenia badania Groupe d’Etude des Lym-
phomes de l’Adulte (GELA), porównującego stosowa-
nie schematu R-CHOP-21 ze schematem R-ACVBP. Do
badania z pierwszorzędowym punktem końcowym
w oparciu o czas wolny od zdarzeń zrekrutowano
380 chorych
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with R-ACVBP. If these results are confirmed with
longer follow-up, it will open the case for moving
to “intensive” R-CHOP for young patients with
adverse outcomes.
Patients with localized disease
Classically, these patients were treated with
3 cycles of CHOP followed by radiation therapy, but
definitive data proving that this was the best treat-
ment are unavailable. Two randomized studies were
run by the GELA comparing chemotherapy with or
without radiation therapy and did not show any be-
nefit in favor of radiation therapy. The first study
in young patients with disease stage I or II compa-
red 3 cycles of CHOP plus radiation therapy to
ACVBP regimen (with only 3 cycles of high-dose
CHOP). Patients treated with ACVBP had longer
EFS and OS [25]. In the second study, elderly pa-
tients with disease stage I or II DLBCL were ran-
domized between 4 cycles of CHOP or 4 cycles of
CHOP plus radiation therapy (Figure 4). EFS and
OS were identical in both arms with more seconda-
ry cancer with radiation therapy [26]. The results
were inferior to what may be expected in good risk
patients, allowing the conclusion that 4 cycles of
CHOP is insufficient for some of these patients.
In rituximab era, a lot of these patients were
treated with 4 cycles of R-CHOP with or without
radiation therapy. However, 4 cycles of R-CHOP is
probably sufficient to cure a majority of these pa-
tients if they respond rapidly with a non-fixing PET
scan [27]. A subgroup of them with persisting dise-
ase represents refractory patients who require
a more intense regimen.
Dose densification of CHOP
and CHOP-like regimens
Concurrently with the studies of rituximab,
investigators have been examining whether they
might improve outcomes in patients with aggressi-
ve lymphoma by increasing the chemotherapy dose
intensity (the amount of drug delivered per unit of
time). Dose intensification can be accomplished
through dose escalation (increasing the amount of
drug given per cycle) or dose densification (redu-
cing the time between treatment cycles).
Several studies have tried to improve results
by modifying the doses given at each cycle or shor-
tening the schedule. The German group (GLSG) has
presented several studies with shortening the in-
terval between cycles from 21 days to 14 days
(CHOP-14) without changing the dose of the regi-
men without, then with rituximab. The first set of
studies compared CHOP-14 to CHOP-21, with or
without etoposide, in young or elderly patients [28, 29].
Theses studies concluded that CHOP-14 was su-
perior to CHOP-21 in elderly patients but not in
young patients. The addition of etoposide improved
outcomes in young patients but not in elderly ones.
Thereafter, the same group has tested the bene-
fit of the addition of rituximab to CHOP-14 (RICOVER
study) [30]. They also tested the number of cycles of
chemotherapy (6 or 8), all patients randomized to ritu-
ximab receiving 8 infusions. Using 6 cycles of CHOP-
-14 (6 × CHOP-14) as the comparator, EFS was signi-
ficantly better in both rituximab arms (Table 2), but OS
was significantly better only with 6 × R-CHOP-14. Ho-
wever, outside Germany, most physicians consider
that the benefit of R-CHOP-14 is not proven and it is
Figure 4. Groupe d’Etude des Lymphomes de l’Adulte
(GELA) study comparing cyclophosphamide, vincristi-
ne, doxorubicin, prednisone (CHOP) to CHOP plus ra-
diation therapy in elderly patients with localized diffuse
large B-cell lymphoma (DLBCL) and International Pro-
gnostic Index (IPI) score = 0 [26]
Rycina 4. Badanie Groupe d’Etude des Lymphomes de
l’Adulte (GELA), w którym porównano stosowanie sche-
matu cyklofosfamid, winkrystyna, doksorubicyna, pred-
nizon (CHOP) bez radioterapii oraz w skojarzeniu z ra-
dioterapią u osób w podeszłym wieku ze zlokalizowaną
postacią chłoniaka rozlanego z dużych komórek B (DLBCL)
oraz z Międzynarodowym Indeksem Prognostycznym
(IPI) = 0 [26]
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Table 2. Studies with CHOP-14 with or without rituximab
Tabela 2. Badania CHOP-14 z lub bez rytuksymabu
Study Design Regimens Number Conclusion Conclusion Conclusion
of patients  on EFS or PFS on OS on safety
NHL-B1 Randomized study CHOP-14 vs. 172 No improvement Trend for G-CSF
[28] in young patients CHOEP-14 vs. 177 for CHOP(E)P-14 improvement mandatory
(double CHOP-21 vs. 176 Improvement of EFS for CHO(E) P-14
randomization) CHOEP-21 185 for CHOEP  (p = 0.05) More
(p = 0.004) No improvement hematological
for CHOEP toxicity with
CHOEP-14
NHL-B2 Randomized CHOP-14 vs. 172 CHOP-14 CHOP-14 G-CSF mandatory
[29] study in elderly CHOEP-14 vs. 169 reduced the reduced the for CHO(E)P-14.
patients (double CHOP-21 vs. 178 risk of an event. risk of dying More hematological
randomization) CHOEP-21 169 No difference from lymphoma. toxicity for
for the addition No improvement etoposide and
of etoposide     for the addition CHOP-14
of etoposide
Halaas Retrospective R-CHOP-14 49 Short follow-up (2 y). Hematology
[55]  analysis Good risk patients. No real and neurological
data to evaluate the efficacy toxicity
Brusamolino Phase II R-CHOP-14 50 2-year EFS and OS inferior More infection
[56]  to the one observe than expected
in the previous report (Pneumocystis
(68% and 72%, respectively) carinii)
Wolf [57] Phase II CHOP-14 30 Nothing in outcome Hematologic
toxicity
Kolstad Retrospective R-CHOEP-14 46 Nothing in outcome 6 cases of
[58] analysis pneumocystis
carinii infection
Mey [59] Phase II R-CHOP-14 10 Evaluation of Pegfilgastrim Grade 3/4
neutropenia in
all patients
Rueda [60] Phase II in R-CHOP-14 80 25% progression with a median Well tolerated;
patients < 70 y follow-up of 2 years mucositis;
19%
hospitalizations
RICOVER-60 Randomized CHOP-14 vs. 1222 R-CHOP-14 R-CHOP-14 More toxic
[30] study, elderly R-CHOP-14 improved EFS. improved OS. events with
patients 6 vs. 8 cycles No difference No difference 8 cycles
between 6 and between 6 and
8 cycles 8 cycles
Cunnigham Randomized R-CHOP-14 vs. 1080 Interim analysis. Short More toxicity
[33]  study R-CHOP-21  follow-up (< 2 y). No difference without G-CSF
between the 2 arms
Delarue Randomized R-CHOP-14 vs. 600 Interim analysis. Short Slightly increased
[34]  study, elderly R-CHOP-21  follow-up (< 2 y). No difference toxicity for
patients  between the 2 arms C-CHOP-14
patients
EFS — event free survival; OS — overall survival; PFS — progression-free survival; NHL — non-Hodgkin lymphoma; CHOP — cyclophosphamide, vincristine,
doxorubicin, prednisone; CHOEP — cyclophosphamide, vincristine, doxorubicin, etoposide, prednisone; R — rituximab; G-CSF — granulocyte colony-stimulating
factor; y — year(s)
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more toxic than standard R-CHOP-21. Two randomi-
zed studies are currently looking at R-CHOP every
2 weeks, but until their results become available
R-CHOP-21 will remain the standard of care.
A subgroup analysis of the RICOVER-60 data
showed no difference in efficacy between 6 and
8 cycles of therapy in patients with either good or
poor prognosis [31]. In contrast, in both subgroups,
TTF was significantly better with R-CHOP-14 than
with CHOP-14. Before and after rituximab infusion
during each cycle in RICOVER-60, blood samples
were taken from 18 participants in the R-CHOP-14
arm. According to pharmacokinetic analysis, ritu-
ximab levels reached their nadir after the first cyc-
le of R-CHOP-14, then increased after each subse-
quent cycle. The researchers speculate that the
nadir would be even lower in an every-3-week sche-
dule of R-CHOP. Thus, as the researchers note, it
appears that dose-dense rituximab (given every
2 weeks), not just dose-dense CHOP, contributed
to the excellent results of the RICOVER-60 trial.
The DSHNHL investigated dose-dense rituximab
in combination with CHOP-14 in an ongoing phase
1 and 2 study, and the early results are encouraging.
Somewhat similar to RICOVER-60, a study
conducted by HOVON and the Nordic Lymphoma
Group compared CHOP-14 and R-CHOP-14 (both
arms with G-CSF support) in older patients, age
> 65 years [32]. This trial was stopped early be-
cause the addition of rituximab to CHOP-14 signi-
ficantly improved the primary outcomes. As shown
in Table 2, the results were not as impressive as
those of RICOVER-60, but are encouraging owing
to the fact that > 60% of these older patients, with
a median age of 72 years, tolerated the regimen.
Since the addition of rituximab to CHOP
(R-CHOP-21) is standard in most countries and
CHOP-14 has been shown to be effective, a key
research question is whether the addition of rituxi-
mab to CHOP-14 (R-CHOP-14) produces further
benefits when compared to R-CHOP-21. Two on-
going trials are addressing this issue by comparing
R-CHOP-21 with R-CHOP-14. A multicenter ran-
domized trial headquartered at University College
London is making this comparison in young and old
patients with untreated DLBCL. An interim analy-
sis was presented this year at the ASCO meeting
[33]. No difference in term of CR rates and PFS
were observed during a short follow-up. G-CSF was
mandatory in the R-CHOP-14 arm and was not in
the R-CHOP-21 arm, and it was not a surprise to
see more neutropenia, febrile neutropenia, and in-
fections in the later arm. In GELA LNH03-6B, pa-
tients between 60 and 80 years old, who had DLBCL
and an aaIPI score ≥ 1, were randomly assigned to
8 cycles of R-CHOP-21 or R-CHOP-14 [34]. This
interim analysis showed an identical response rate
and a non-statistically significant difference in fa-
vor of R-CHOP-21 for EFS; the survival being iden-
tical. R-CHOP-14 patients were more likely to have
more infections, mucositis, and needed more hospi-
talizations.
Thus, two interim analyses did not show any
difference between R-CHOP-14 and R-CHOP-21.
It is highly improbable that the complete analyses
with a longer follow-up will show this difference.
We may conclude that both regimens are equiva-
lent for patients with DLBCL.
Dose intensification of R-CHOP
Patients with DLBCL whose IPI scores indi-
cate they are at high-intermediate or high risk have
less than 50% chance of being cured with R-CHOP
[35]. Even in the MInT study of younger adults with
a good prognosis, the outcomes varied among tho-
se who received rituximab plus CHOP-like chemo-
therapy: In the less favorable group (bulky disease,
age-adjusted IPI [aaIPI] = 1, or both), 3-year EFS
with rituximab was 78%, compared to 97% in the
more favorable group (aaIPI = 0, no bulky disease)
[22, 36]. Because the addition of rituximab to CHOP
has become the standard of care for DLBCL, inve-
stigators are examining the effects of administering
higher doses of chemotherapy agents, higher dose
of rituximab or combining another drug to R-CHOP.
Before and after rituximab infusion during each
cycle in RICOVER-60, blood samples were taken
from 18 participants in the R-CHOP-14 arm. Accor-
ding to pharmacokinetic analysis, rituximab levels
reached their nadir after the first cycle of R-CHOP-
-14, then increased after each subsequent cycle.
Therefore the DSHNHL investigated dose-dense
rituximab in combination with CHOP-14 in an on-
going phase 1 and 2 study, and the early results are
encouraging [37]. In this study, rituximab was ad-
ministered every week for the first 2 cycles and
pharmacokinetics data confirmed the disappearan-
ce of this nadir. A randomized study is ongoing to
test the hypothesis that higher blood level of ritu-
ximab is associated with higher response rate and
PFS. Recently, it was demonstrated in mice studies
that the tumor volume influenced the pharmacoki-
netic of rituximab and response to treatment [38].
The authors hypothesized that higher doses of ri-
tuximab would increase the efficacy of such thera-
py. This hypothesis is being currently tested in
patients with DLBCL.
37www.hematologia.viamedica.pl
Anne-Sophie Michallet, Bertrand Coiffier, Treatment of patients with DLBCL
The other way to increase the intensity dose
is to increase the dose of CHOP or CHOP-like re-
gimens. The DSHNHL conducted a randomized
study to compare R-CHOEP-14 with a dose-esca-
lated version in younger patients with aggressive
NHL and a good prognosis [39]. The dose-escalated
regimen (Mega-CHOEP) comprised cyclophospha-
mide 1400 mg/m2, doxorubicin 65 mg/m2, vincristi-
ne 2 mg, etoposide 175 mg/m2 for 3 cycles (× 3), and
prednisone 100 mg × 5. Mega-CHOEP was more
toxic than standard treatment, and there was no
difference in the time to treatment failure (TTF, the
primary endpoint) or OS. Neither the low-risk nor
the low-intermediate-risk subgroup benefited from
the dose escalation. The cause of these unexpec-
ted results is not known.
However, the GELA has tested the combina-
tion of rituximab to its high-dose CHOP, ACVBP
regimen (Figure 5), and has found to be superior to
R-CHOP in two studies. The first study was a pha-
se II study of R-ACVBP followed by autologous
transplant in first CR in young patients with high
risk DLBCL [40]. EFS was above 75% at 3 years.
These results were compared with historical results
in the same group of patients with the same treat-
ment design, but without rituximab. The results
showed 15% improvement in EFS demonstrating
very good results with R-ACVBP in a subgroup of
patients with high risk DLBCL. Another study com-
pared the standard R-CHOP with R-ACVBP follo-
wed by sequential consolidation. In the interim ana-
lysis, there was a trend in favor of R-ACVBP for
PFS. Final analysis of this study will be performed
next year.
The last possible improvement could be the
addition of another drug to R-CHOP. The addition
of etoposide was tested by the German group: in
elderly patients, R-CHOEP was more toxic but in
young patients it seemed to be associated with good
overall activity. Other targeted drugs are curren-
tly being tested, but no data have been made ava-
ilable yet: bevacizumab in a study comparing RA-
-CHOP to R-CHOP; lenalidomide in the R2-CHOP;
or enzastaurin.
The conclusion of the discussed study is as
follows: the standard R-CHOP is not sufficient in a
subgroup of patients with high score IPI. However,
because of the unavailability of the currently tested
hypotheses, it is difficult to propose a ‘standard’
regimen for these patients.
Figure 5. ACVBP regimen used within the different Groupe d’Etude des Lymphomes de l’Adulte (GELA) studies since
1984 [24, 61–63]
Rycina 5. Schemat ACVBP stosowany w różnych badaniach Groupe d’Etude des Lymphomes de l’Adulte (GELA) od
1984 roku [24, 61–63]
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Maintaining planned dose intensity
CHOP-based therapy has a number of dose-li-
miting toxicities, such as chemotherapy-induced
neutropenia, particularly in older patients. In the
NHL-B2 trial, the most common grade 3 or 4 toxi-
city was leukocytopenia, which occurred in 72% of
patients who received CHOP-21, and in 70% of those
who were treated with CHOP-14 [29]. Grade 3 or
4 thrombocytopenia occurred in 8% and 15% of pa-
tients, respectively, and grade 3 or 4 anemia affec-
ted 13% and 20%, respectively. Along with alope-
cia and nausea or vomiting, common non-hemato-
logic grade 3 or 4 toxicities included infection,
cardiac toxicity, neurological toxicity, lung toxici-
ty, and, in the CHOP-14 arm, mucositis.
If CHOP side effects require dose reductions,
dose delays, or chemotherapy withdrawal, patient
survival can be negatively affected by the reduction
in relative dose intensity (RDI, the proportion of the
intended chemotherapy dose that a patient receives
during a specified time period). In Belgium and the
United Kingdom, audits of 289 NHL patients rece-
iving CHOP-21 showed that 5-year OS was signifi-
cantly associated with RDI £ 90% (hazard ratio,1.8;
95% confidence interval [CI], 1.1–2.8) [41]. These
observations confirm earlier reports of associations
between reduced RDI and reduced OS in patients
with NHL [42–44].
Research conducted in routine community
practice has documented that febrile neutropenia
(FN) is a common cause of reduced RDI in patients
with NHL. In Western Europe, a prospective obse-
rvational study by Pettengell et al. [45] examined
the impact of FN on chemotherapy in 34 centers.
Of 240 patients with NHL, most received CHOP-
-like-21 (74%) or CHOP-like-14 (17%) chemothe-
rapy. FN occurrence was ≥ 20% with CHOP-like-21
and most other NHL regimens. For patients with
NHL the mean RDI was only 86%, and 32% of pa-
tients had low RDI (£ 85%). Other risk factors for
low RDI were advancing age, Eastern Cooperative
Oncology Group performance status ≥ 2, fewer cyc-
les of CSF administration, and first-cycle FN.
Pettengell [45] conclude that routine Europe-
an practice should be revised to include primary
prophylaxis with G-CSF if the patient will receive
a chemotherapy regimen associated with an FN in-
cidence ≥ 20% or is expected to receive less than
optimal RDI. This recommendation echoes the re-
cently published guidelines of the European Orga-
nization for Research and Treatment of Cancer
(EORTC), which conclude that there is a strong and
consistent evidence that G-CSF prophylaxis can
maintain chemotherapy at the desired dose, inten-
sity or density and minimize delays [46].
The future of therapy for aggressive NHL
The success of rituximab in the treatment of
aggressive NHL has prompted the investigation of
monoclonal antibodies that target other surface pro-
teins and antigens commonly expressed in B-cell
lymphoma. The most promising are antibodies aga-
inst CD40, B-cell–activating factor of the TNF fa-
mily (BAFF), and receptors for TRAIL (TNF-a-re-
lated apoptosis-inducing ligand, also known as
Apo2L) [47]. Another approach is to use small mo-
lecules to target intracellular pathways that have
a role in tumor cell survival and growth. For exam-
ple, a multicenter phase 2 study using bortezomib,
a protease inhibitor, in patients with relapsed or
refractory mantle cell lymphoma, showed that it
provided substantial activity in terms of durable and
complete response, with predictable and manage-
able toxicity [48]. Although the effort is largely the-
oretical at this time, it may also be possible to iden-
tify small molecules to target certain classes of
mitotic kinases that regulate cell division and mi-
tosis. Lenalidomide, an agent with mechanisms of
action that differ from chemotherapy or monoclo-
nal antibodies, has activity in lymphoma and may
be combined with R-CHOP to improve response
rate or decrease relapse rate [49–53]. Finally, re-
searchers are combining bevacizumab or thalidomi-
de with rituximab, CHOP, or R-CHOP to determi-
ne whether it might be worthwhile to target tumor
angiogenesis in NHL [54]. Although most of these
agents and regimens are still in early development,
it seems likely that at least a few more targeted
therapies for NHL will soon be available.
Conclusion
The addition of rituximab to CHOP and dose
intensification of CHOP are important advances in
the treatment of NHL. The results of ongoing stu-
dies will refine further treatment options. The two
more important questions for improving the out-
comes in patients with DLBCL are how to recogni-
ze and treat patients with high risk of failure to
R-CHOP or relapse after R-CHOP. Several ongoing
studies are testing the above aspects and the results
should be published in the next couple of years.
39www.hematologia.viamedica.pl
Anne-Sophie Michallet, Bertrand Coiffier, Treatment of patients with DLBCL
References
1. Sandin S., Hjalgrim H., Glimelius B., Rostgaard K., Pukkala E.,
Askling J. Incidence of non-Hodgkin’s lymphoma in Sweden,
Denmark, and Finland from 1960 through 2003: an epidemic that
was. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 1295–300.
2. Broccia G, Cocco P, Casula P. Incidence of non-Hodgkin’s lym-
phoma and Hodgkin’s disease in Sardinia, Italy: 1974–1993. Hae-
matologica 2001; 86: 58–63.
3. Morgan G., Vornanen M., Puitinen J., et al. Changing trends in
the incidence of non- Hodgkin’s lymphoma in Europe. Ann. Oncol.
1997; 8: 49–54.
4. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P.
Estimates of the cancer incidence and mortality in Europe in
2006. Ann. Oncol. 2007; 18: 581–92.
5. Boyle P., Ferlay J. Cancer incidence and mortality in Europe,
2004. Ann. Oncol. 2005; 16: 481–488.
6. The Non-Hodgkin’s Lymphoma Classification Project. A Clini-
cal Evaluation of the International Lymphoma Study Group
Classification of Non- Hodgkin’s Lymphoma. Blood 1997; 89:
3909–3918.
7. Maartense E., Kluin-Nelemans H.C., le Cessie S., Kluin P.M.,
Snijder S., Noordijk E.M. Different age limits for elderly pa-
tients with indolent and aggressive non-Hodgkin lymphoma
and the role of relative survival with increasing age — analysis
of a population-based non- Hodgkin’s lymphoma registry. Can-
cer 2000; 89: 2667–2676.
8. McKelvey E.M., Gottlieb J.A., Wilson H.E., et al. Hydroxyl-
daunomycin (adriamycin) combination chemotherapy in malig-
nant lymphoma. Cancer 1976; 38: 1484–1493.
9. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of
a Standard Regimen (CHOP) with Three Intensive Chemo-
therapy Regimens for Advanced Non- Hodgkin’s Lymphoma.
N. Engl. J. Med. 1993; 328: 1002–1006.
10. The International Non-Hodgkin’s Lymphoma Prognostic Fac-
tors Project. A predictive model for aggressive non-Hodgkin’s
lymphoma. N. Engl. J. Med. 1993; 329: 987–994.
11. de Jong D., Rosenwald A., Chhanabhai M., et al. Immunohis-
tochemical prognostic markers in diffuse large B-cell lympho-
ma: validation of tissue microarray as a prerequisite for broad
clinical applications — a study from the Lunenburg Lymphoma
Biomarker Consortium. J. Clin. Oncol. 2007; 25: 805–812.
12. The NHLClassification Project. Effect of age on the characteris-
tics and clinical behavior of non-Hodgkin lymphoma patients.
Ann. Oncol. 1997; 8: 973–978.
13. Coiffier B. What treatment for elderly patients with aggressive
lymphoma? Ann. Oncol. 1994; 5: 873–875.
14. Thieblemont C., Coiffier B. Lymphoma in older patients. J. Clin.
Oncol. 2007; 25: 1916–1923.
15. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus
rituximab compared with CHOP alone in elderly patients with
diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346:
235–242.
16. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of
the R-CHOP study in the treatment of elderly patients with
diffuse large B-cell lymphoma: a study by the Groupe d’Etude
des Lymphomes de l’Adulte . J. Clin. Oncol. 2005; 23: 4117–4126.
17. Coiffier B., Gisselbrecht C., Bosly A., et al. 10 years follow-up of
the GELA LNH98.5 Study, first randomized study comparing
R-CHOP to CHOP chemotherapy in patients with diffuse large
B-cell lymphoma. Blood 2009; 114: 1440 [abstract 3741].
18. Coiffier B., Feugier P., Mounier N., et al. Long-term results of
the GELA study comparing R-CHOP and CHOP chemotherapy
in older patients with diffuse large B-cell lymphoma show good
survival in poor risk patients. J. Clin. Oncol. 2007; 25: 443s.
19. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-
-CHOP versus CHOP alone or with maintenance rituximab in
older patients with diffuse large B-cell lymphoma. J. Clin. Oncol.
2006; 24: 3121–3127.
20. Coiffier B. Increasing chemotherapy intensity in aggressive lym-
phomas: A renewal? J. Clin. Oncol. 2003; 21: 2457–2459.
21. Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of
combined CHOP plus rituximab therapy dramatically improved
outcome of diffuse large B-cell lymphoma in British Columbia.
J. Clin. Oncol. 2005; 23: 5027–5033.
22. Pfreundschuh M., Trumper L., Osterborg A., et al. CHOP-like
chemotherapy plus rituximab versus CHOP-like chemotherapy
alone in young patients with good-prognosis diffuse large-B-cell
lymphoma: a randomised controlled trial by the MabThera Inter-
national Trial (MInT) Group. Lancet Oncol. 2006; 7: 379–391.
23. Jost L.M., Kloke O., Stahel R.A. ESMO Minimum Clinical Re-
commendations for diagnosis, treatment and follow-up of newly
diagnosed large cell non-Hodgkin’s lymphoma. Ann. Oncol.
2005; 16 (Suppl 1): i58–i59.
24. Tilly H., Lepage E., Coiffier B., et al. Intensive conventional
chemotherapy (ACVBP regimen) compared with standard
CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Blood 2003; 102: 4284–4289.
25. Reyes F., Lepage E., Ganem G., et al. Chemotherapy alone with
the intensified ACVBP plus sequential consolidation regimen
compared with three cycles of standard CHOP plus involved
field radiotherapy for low risk localized aggressive lymphoma in
patients less than 60 years of age. N. Engl. J. Med. 2005; 352:
1197–1205.
26. Bonnet C., Fillet G., Mounier N., et al. CHOP alone compared
with CHOP plus radiotherapy for localized aggressive lympho-
ma in elderly patients: a study by the Groupe d’Etude des Lym-
phomes de l’Adulte. J. Clin. Oncol. 2007; 25: 787–792.
27. Sehn L., Savage K., Hoskins P., et al. Limited-stage DLBCL
patients with a negative PET scan following three cycles of
R-CHOP have an exellent outcome following abbreviated immu-
no-chemotherapy alone. Ann. Oncol. 2008; 19 (Suppl. 4): 100.
28. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or
3-weekly CHOP chemotherapy with or without etoposide for
the treatment of young patients with good-prognosis (normal
LDH) aggressive lymphomas: results of the NHL-B1 trial of the
DSHNHL. Blood 2004; 104: 626–633.
29. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or
3-weekly CHOP chemotherapy with or without etoposide for the
treatment of elderly patients with aggressive lymphomas: results
of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641.
30. Pfreundschuh M., Schubert J., Ziepert M., et al. Six versus eight
cycles of bi-weekly CHOP-14 with or without rituximab in el-
derly patients with aggressive CD20+ B-cell lymphomas: a ran-
domised controlled trial (RICOVER-60). Lancet Oncol. 2008; 9:
105–116.
31. Held G., Schubert J., Reiser M., Pfreundschuh M. Dose-intensi-
fied treatment of advanced-stage diffuse large B-cell lympho-
mas. Semin. Hematol. 2006; 43: 221–229.
32. Sonneveld P., Putten W., Biesma D., et al. Phase III trial of
2-weekly CHOP with rituximab for aggressive B-cell non-
-Hodgkin’s lymphoma in elderly patients. Blood 2006; 108: 66a
[abstract 210].
40
Hematologia 2010, tom 1, nr 1
www.hematologia.viamedica.pl
33. Cunningham D., Smith P., Mouncey P., et al. A phase III trial
comparing R-CHOP 14 and R-CHOP 21 for the treatment of
patients with newly diagnosed diffuse large B-cell non-Hodgkin’s
lymphoma. (2009 ASCO Annual Meeting). J. Clin. Oncol. 2009;
27 (Suppl.): 15s [abstract 8506].
34. Delarue R., Tilly H., Salles G., et al. R-CHOP14 compared to R-
-CHOP21 in elderly patients with diffuse large B-cell lymphoma:
results of the interim analysis of the LNH03-6B GELA Study.
Blood 2009; 114: 169 [abstract 406].
35. Coiffier B. State-of-the-Art Therapeutics: Diffuse Large B-Cell
Lymphoma. J. Clin. Oncol. 2005; 23: 6387–6393.
36. Pfreundschuh M., Ho A.D., Cavallin-Stahl E., et al. Prognostic
significance of maximum tumour (bulk) diameter in young pa-
tients with good-prognosis diffuse large-B-cell lymphoma treat-
ed with CHOP-like chemotherapy with or without rituximab: an
exploratory analysis of the MabThera International Trial Group
(MInT) study. Lancet Oncol. 2008; 9: 435–444.
37. Poeschel V., Nickelsen M., Hanel M., et al. Dose-dense ritu-
ximab in combination with biweekly CHOP-14 for elderly pa-
tients with diffuse large B-cell lymphoma (DLBCL): results of
a phase-I/II and pharmacokinetic study of the German High-
-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Blood 2006; 108: 774a [abstract 2738].
38. Dayde D., Ternant D., Ohresser M., et al. Tumor burden influ-
ences exposure and response to rituximab: pharmacokinetic-
-pharmacodynamic modeling using a syngeneic bioluminescent
murine model expressing human CD20. Blood 2009; 113:
3765–3772.
39. Schmitz N., Nickelsen M., Ziepert M., et al. Aggressive chemo-
therapy (CHOEP-14) and rituximab or high-dose therapy (Mega-
CHOEP) and rituximab for young, high-risk patients with ag-
gressive B-cell lymphoma: results of the MegaCHOEP trial of
the German High-Grade Non-Hodgkin Lymphoma Study Group
(DSHNHL). Blood 2009; 114: 168 [abstract 404].
40. Gisselbrecht C., Fitoussi O., Belhadj K., et al. Survival impact of
rituximab combined to ACVBP (R-ACVBP) in 209 poor risk dif-
fuse large B-cell lymphoma (DLBCL) patients treated with up-
front high-dose consolidative autotransplantation (HDC): a GELA
phase II study. Blood 2008; 112: 286 [abstract 771].
41. Bosly A., Bron D., Van Hoof A., et al. Achievement of optimal
average relative dose intensity and correlation with survival in
diffuse large B-cell lymphoma patients treated with CHOP.
Ann. Hematol. 2008; 87: 277–283.
42. Lepage E., Gisselbrecht C., Haioun C., et al. Prognostic signifi-
cance of received relative dose intensity in non-Hodgkin’s lym-
phoma patients: application to LNH-87 protocol. Ann. Oncol.
1993; 4: 651–656.
43. Epelbaum R., Faraggi D., Ben-Arie Y., et al. Survival of diffuse
large cell lymphoma. A multivariate analysis including dose in-
tensity variables. Cancer 1990; 66: 1124–1129.
44. Kwak L.W., Halpern J., Olshen R.A., Horning S.J. Prognostic
significance of actual dose intensity in diffuse large cell lympho-
ma: results of a tree structured survival analysis. J. Clin. Oncol.
1990; 8: 963–977.
45. Pettengell R., Bosly A., Szucs T.D., et al. Multivariate analysis
of febrile neutropenia occurrence in patients with non-Hodgkin
lymphoma: data from the INC-EU Prospective Observational
European Neutropenia Study. Br. J. Haematol. 2009; 144:
677–685.
46. Pettengell R., Aapro M., Brusamolino E., et al. Implications of
the European Organisation for Research And Treatment Of Can-
cer (EORTC) guidelines on the use of granulocyte colony-sti-
mulating factor (G-CSF) for lymphoma care. Clin. Drug Investig.
2009; 29: 491–513.
47. Fayad L., Younes A. Novel treatment strategies for aggressive
non-Hodgkin’s lymphoma. Expert Opin. Pharmacother. 2006; 7:
733–748.
48. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II
study of bortezomib in patients with relapsed or refractory man-
tle cell lymphoma. J. Clin. Oncol. 2006; 24: 4867–4874.
49. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide
oral monotherapy produces a high response rate in patients with
relapsed or refractory mantle cell lymphoma. Br. J. Haematol.
2009; 145: 344–349.
50. Ramsay A.G., Clear A.J., Kelly G., et al. Follicular lymphoma
cells induce T-cell immunologic synapse dysfunction that can be
repaired with lenalidomide: implications for the tumor microen-
vironment and immunotherapy. Blood 2009; 114: 4713–4720.
51. Wiernik P.H., Lossos I.S., Tuscano J.M., et al. Lenalidomide
monotherapy in relapsed or refractory aggressive Hodgkin’s
lymphoma. J. Clin. Oncol. 2008; 26: 4952–4957.
52. Witzig T.E., Wiernik P.H., Moore T., et al. Lenalidomide oral
monotherapy produces durable responses in relapsed or refrac-
tory indolent Hodgkin’s lymphoma. J. Clin. Oncol. 2009; 27:
5404–5409.
53. Zhang L., Qian Z., Cai Z., et al. Synergistic antitumor effects of
lenalidomide and rituximab on mantle cell lymphoma in vitro
and in vivo. Am. J. Hematol. 2009; 84: 553–559.
54. Reiners K.S., Gossmann A., von Strandmann E.P., Boll B.,
Engert A., Borchmann P. Effects of the anti-VEGF monoclonal
antibody bevacizumab in a preclinical model and in patients with
refractory and multiple relapsed Hodgkin lymphoma. J. Immu-
nother. 2009; 32: 508–512.
55. Halaas J.L., Moskowitz C.H., Horwitz S., et al. R-CHOP-14 in
patients with diffuse large B-cell lymphoma: feasibility and pre-
liminary efficacy. Leuk. Lymphoma 2005; 46: 541–547.
56. Brusamolino E., Rusconi C., Montalbetti L., et al. Dose-dense
R-CHOP-14 supported by pegfilgrastim in patients with diffuse
large B-cell lymphoma: a phase II study of feasibility and toxici-
ty. Haematologica 2006; 91: 496–502.
57. Wolf M., Bentley M., Marlton P., et al. Pegfilgrastim to support
CHOP-14 in elderly patients with non-Hodgkin lymphoma.
Leuk. Lymphoma 2006; 47: 2344–2350.
58. Kolstad A., Holte H., Fossa A., Lauritzsen G.F., Gaustad P.,
Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lympho-
ma patients treated with the rituximab-CHOEP-14 regimen.
Haematologica 2007; 92: 139–140.
59. Mey U.J., Maier A., Schmidt-Wolf I.G., et al. Pegfilgrastim as
hematopoietic support for dose-dense chemoimmunotherapy
with R-CHOP-14 as first-line therapy in elderly patients with diffuse
large B cell lymphoma. Support Care Cancer 2007; 15: 877–884.
60. Rueda A., Sabin P., Rifa J., et al. R-CHOP-14 in patients with
diffuse large B-cell lymphoma younger than 70 years: a multi-
centre, prospective study. Hematol. Oncol. 2008; 26: 27–32.
61. Coiffier B. Fourteen years of high-dose CHOP (ACVB regimen):
preliminary conclusions about the treatment of aggressive-lym-
phoma patients. Ann. Oncol. 1995; 6: 211–217.
62. Gisselbrecht C., Lepage E., Molina T., et al. Shortened first-line
high-dose chemotherapy for patients with poor-prognosis ag-
gressive lymphoma. J. Clin. Oncol. 2002; 20: 2472–2479.
63. Coiffier B., Reyes F. Best treatment of aggressive non-Hodgkin’s
lymphoma: a French perspective. Oncology 2005; 18: 7–15.
